Drug Delivery–mediated Control of RNA Immunostimulation

[1]  Svetlana Shulga Morskaya,et al.  RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy , 2009, Antimicrobial Agents and Chemotherapy.

[2]  Michael S. Goldberg,et al.  Development of lipidoid-siRNA formulations for systemic delivery to the liver. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[4]  Svetlana Shulga Morskaya,et al.  5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma , 2008, Nature Medicine.

[5]  A. Judge,et al.  Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. , 2008, Human gene therapy.

[6]  Dale L. Greiner,et al.  T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice , 2008, Cell.

[7]  Robert Langer,et al.  Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates , 2008, Proceedings of the National Academy of Sciences.

[8]  Robert Langer,et al.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.

[9]  B. Williams,et al.  Determinants of cytokine induction by small interfering RNA in human peripheral blood mononuclear cells. , 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[10]  Justine R. Smith,et al.  Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 , 2008, Nature.

[11]  S. Elbashir,et al.  Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). , 2008, Antiviral research.

[12]  K. Heeg,et al.  Modifications in Small Interfering RNA That Separate Immunostimulation from RNA Interference1 , 2008, The Journal of Immunology.

[13]  K. Spurgers,et al.  Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses , 2008, Antiviral Research.

[14]  熊谷 雄太郎,et al.  Alveolar macrophages are the primary interferon-α producer in pulmonary infection with RNA viruses , 2008 .

[15]  R. Mahato,et al.  RNAi for Treating Hepatitis B Viral Infection , 2007, Pharmaceutical Research.

[16]  John J Rossi,et al.  Genetic therapies against HIV , 2007, Nature Biotechnology.

[17]  A. Krieg.  The toll of too much TLR7. , 2007, Immunity.

[18]  M. Kohara,et al.  Therapeutic application of RNA interference for hepatitis C virus. , 2007, Advanced drug delivery reviews.

[19]  A. Judge,et al.  2'-O-methyl-modified RNAs act as TLR7 antagonists. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  V. Hornung,et al.  Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response. , 2007, Blood.

[21]  M. Sioud.  RNA interference and innate immunity. , 2007, Advanced drug delivery reviews.

[22]  A. Krieg.  Toll-free vaccines? , 2007, Nature Biotechnology.

[23]  Richard L. Miller,et al.  Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. , 2007, Antiviral research.

[24]  P. Jahrling,et al.  Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge Is Conferred by RNA Interference , 2006, The Journal of infectious diseases.

[25]  A. Lee,et al.  Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  D. Schaffer,et al.  Antiviral RNAi therapy: emerging approaches for hitting a moving target , 2005, Gene Therapy.

[27]  S. Akira,et al.  Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8 , 2005, The Journal of experimental medicine.

[28]  B. Williams,et al.  Activation of the mammalian immune system by siRNAs , 2005, Nature Biotechnology.

[29]  N. Zhong,et al.  Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque , 2005, Nature Medicine.

[30]  Keith Bowman,et al.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.

[31]  M. Sioud.  Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. , 2005, Journal of molecular biology.

[32]  R. Langer,et al.  Exploring polyethylenimine‐mediated DNA transfection and the proton sponge hypothesis , 2005, The journal of gene medicine.

[33]  Qing Ge,et al.  Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Judge,et al.  Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA , 2005, Nature Biotechnology.

[35]  S. Akira,et al.  Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7 , 2005, Nature Medicine.

[36]  M. Tomai,et al.  Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8 , 2005, Journal of Immunology.

[37]  S. Barik,et al.  Inhibition of respiratory viruses by nasally administered siRNA , 2005, Nature Medicine.

[38]  Qing Ge,et al.  Inhibition of influenza virus production in virus-infected mice by RNA interference. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  T. Tumpey,et al.  Protection against lethal influenza virus challenge by RNA interference in vivo. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Jianzhu Chen,et al.  Use of siRNAs to prevent and treat influenza virus infection. , 2004, Virus research.

[41]  D. Weissman,et al.  Small Interfering RNAs Mediate Sequence-Independent Gene Suppression and Induce Immune Activation by Signaling through Toll-Like Receptor 31 , 2004, The Journal of Immunology.

[42]  Shizuo Akira,et al.  Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA , 2004, Science.

[43]  F. Szoka,et al.  Chloride Accumulation and Swelling in Endosomes Enhances DNA Transfer by Polyamine-DNA Polyplexes* , 2003, Journal of Biological Chemistry.

[44]  E. Moss,et al.  Small-interfering RNAs in the radar of the interferon system , 2003, Nature Cell Biology.

[45]  S. Ikehara,et al.  Heterogeneity of Dendritic Cells in the Mouse Liver: Identification and Characterization of Four Distinct Populations 1 , 2003, The Journal of Immunology.

[46]  Michael T. McManus,et al.  RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[47]  R. Flavell,et al.  Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 , 2001, Nature.

[48]  H. Yang,et al.  Immunoprophylactic strategies against respiratory influenza virus infection. , 2001, Vaccine.

[49]  Phillip D. Zamore,et al.  RNA Interference , 2000, Science.

[50]  P. Sharp,et al.  RNAi Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals , 2000, Cell.

[51]  J. Dahlberg,et al.  Molecular biology. , 1977, Science.